Community Based Management of Diabetes in Nepal

Type 2 Diabetes Mellitus Clinical Trial

— COBIN-D  

Official title:

Community Based Intervention for Management of Diabetes in Nepal (COBIN-D): A Cluster Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03304158
• Other study ID #: AUBIS123
• Status: Completed
• Phase: N/A
• Start date: June 1, 2017
• Est. completion date: January 31, 2019

Study information

• Verified date: August 2020
• Source: University of Aarhus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 2 diabetes is the largest growing concern across the globe, and this is particularly apparent in developing countries, including Nepal. Despite the growing burden and chronic nature of diabetes, prevention and control of this disease is far from adequate setting in Nepal. Moreover, there is lack of evidence on effectiveness and affordability of a population approach on reducing blood glucose level among diabetes persons. The main aim of this study is to determine the effect of Female Community Health Volunteers' (FCHVs)-led family-based health education and screening on blood sugar level in adults at community level in Nepal. This is a community-based cluster randomized controlled trial involving family based health education through FCHVs in Nepal. People ≥25 years of age listed in the Community-Based Management of Hypertension (COBIN) study and who were diabetics are eligible for eligible for participation in the study. FCHVs will conduct family based health education and fasting blood glucose measurements in the treatment arm vs not any interventions in the control arm. Independent assessors will conduct the baseline and end line assessment of the intervention. Intention to treat analysis and per protocol analysis will be used in analysis to detect significant differences between treatment and control group participants at baseline and follow up. For individual outcomes, proportions will be compared using Chi-square test and continuous measures will be compared using t-tests. Random effect mixed regression analysis will be adjusted for age and sex. Since randomisation will be at the cluster level in the study, a random-effect model will be used to account for clustering effect. Effectiveness of the intervention will be tested by analysis of covariance, which will allow us to adjust for baseline differences between groups. It is anticipated that the study can give valuable information regarding effectiveness, acceptability, and feasibility of an innovative way to improve diabetes management. Assessing the FCHVs' ability to address diabetes may contribute to develop a policy that can be scaled-up to a national level.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 224
• Est. completion date: January 31, 2019
• Est. primary completion date: September 30, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Those =25 years of age and listed in the COBIN study

• Those who participated in our prevalence study

• Those who give consent to participate in our intervention study

• Those who do not have any plan to migrate from the study area for at least 1 year

• Those who are non-pregnant women

• Those who are not severely ill

Exclusion Criteria:

• Those who do not give consent

• Those who are pregnant women

• Those who are severely ill

• Those who have plans to migrate from the study area within 1 year

Related Conditions & MeSH terms

• Diabetes Mellitus
• Type 2 Diabetes Mellitus

Intervention

Behavioral:
• FCHV visit
FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose

Locations

Country	Name	City	State
Nepal	A semi-urban area of Pokhara-Lekhnath Metropolitan City of Nepal	Pokhara

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus

Country where clinical trial is conducted

Nepal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean fasting blood glucose level	Change in mean fasting blood glucose level in diabetes populations	1 year